Jun 1, 2009
By:Cheryl Guttman
Ustekinumab (Centocor) pivotal trial data provide further evidence of the quality-of-life benefits derived when patients with moderate-to-severe psoriasis can maintain disease control.
 |
Jun 1, 2009
By:Cheryl Guttman
The investigational anti-tumor necrosis factor (TNF) monoclonal antibody golimumab (Centocor) is being evaluated as a once-a-month subcutaneous injection for the treatment of psoriatic arthritis in a Phase 3 trial that enrolled approximately 400 patients.
|
May 1, 2009
By:Ilya Petrou, M.D.
Biologic therapy is proven to increase the quality of life in adult patients suffering from moderate-to-severe psoriasis. A recent study shows that etanercept (Enbrel, Immunex) can achieve similar positive results in children and adolescents, offering hope to this patient population.
|
May 1, 2009
By:Ilya Petrou, M.D.
Recent study results indicate that there is a relationship between the severity of psoriasis and CRP levels, as well as BMI in pediatric patients. These patients are also at a higher cardiovascular risk, begging the need for treatment strategies in terms of lipid-lowering therapies.
|
Apr 1, 2009
By:Lisa B. Samalonis
Advances in pediatric inflammatory skin diseases, such as psoriasis, acne and atopic dermatitis, have led to new therapies and better understanding of the underlying disease processes.
|
Experts often favor aggressive approach
Mar 7, 2009
By:John Jesitus
San Francisco — Children with skin diseases such as severe psoriasis, eczema and hemangiomas are benefiting from new treatments and new knowledge about existing treatments, experts say.
|
Phototherapy remains useful
Mar 6, 2009
By:Susan Schell
San Francisco — Phototherapy still plays a very useful role in the dermatologist’s treatment armamentarium, despite therapeutic advances and the advent of biologic drugs for treating many skin diseases, said Michael D. Zanolli, M.D., of Nashville, Tenn., who spoke Friday at the 67th Annual Meeting of the American Academy of Dermatology here.
|
Mar 1, 2009
By:Louise Gagnon
Combination therapy has a role in the treatment of psoriasis, particularly when there is a loss of response with monotherapy using biologic agents. Methotrexate, systemic retinoids, or phototherapy can be part of a combined therapy with biologic agents.
|
Mar 1, 2009
By:John Jesitus
A new coal tar treatment for psoriasis sidesteps major formulation challenges that hindered patient acceptance of previous coal tar products, a clinical investigator says.
|
| 
